Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer
Larotrectinib demonstrated long durability, extended survival and manageable safety in patients with TRK fusion GI cancer, including those with MSI-H CRC. This supports the wider adoption of next-generation sequencing testing for NTRK gene fusions in patients with GI cancer.
Authors
- Damian Tobias Rieke (ORCID: https://orcid.org/0000-0003-0027-7977)
- Domnita-Ileana Burcoveanu
- David S. Hong (ORCID: https://orcid.org/0000-0001-8721-1609)
- Lin Shen (ORCID: https://orcid.org/0000-0001-8101-4129)
- Jordan Berlin (ORCID: https://orcid.org/0000-0001-7571-2385)
- Changsong Qi (ORCID: https://orcid.org/0000-0001-9157-3768)
- Timothy Lewis Cannon (ORCID: https://orcid.org/0000-0001-5033-3071)
- Elena Garralda (ORCID: https://orcid.org/0000-0002-4412-7842)
- Alexander Edward Dela Cruz Drilon (ORCID: https://orcid.org/0000-0001-6806-9061)
- Chiara Mussi (ORCID: https://orcid.org/0000-0001-5598-9969)
- Thierry André (ORCID: https://orcid.org/0000-0002-5103-7095)
- Hyun Cheol Chung (ORCID: https://orcid.org/0000-0002-0920-9471)
- Tianshu Liu (ORCID: https://orcid.org/0000-0002-8604-6311)
- Rui‐Hua Xu (ORCID: https://orcid.org/0000-0001-9771-8534)
- Natascha Neu
- Antoine Italiano
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Université de Bordeaux (FR)
- Sun Yat-sen University (CN)
- Yonsei University (KR)
- Peking University (CN)
- Cornell University (US)
- Fudan University (CN)
- Inova Fairfax Hospital (US)
- Sorbonne Université (FR)
- Peking University Cancer Hospital (CN)
- Bayer (Switzerland) (CH)
- Bayer (Italy) (IT)
- Zhongshan Hospital (CN)
- Vall d'Hebron Hospital Universitari (ES)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
- Institut Bergonié (FR)
- Centre de Recherche Saint-Antoine (FR)
- Sun Yat-sen University Cancer Center (CN)
- Charité - Universitätsmedizin Berlin (DE)
- Vanderbilt University Medical Center (US)
Publication Details
- Journal
- European Journal of Cancer
- Published
- 2025-03-04
- DOI
- https://doi.org/10.1016/j.ejca.2025.115338
- Citations
- 18
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 27.33
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- BeiGene
- Incyte
- Celltrion
- Seagen
- Springworks Therapeutics
- Bayer HealthCare
- Daiichi-Sankyo
- Astellas Pharma
- Servier
- PharmaMar
- Ipsen
- Aptitude Health